88 results
8-K
EX-99.1
EQ
Equillium Inc
9 May 24
Equillium Reports First Quarter 2024 Financial Results and Provides Recent Clinical Highlights
4:05pm
of 2023.
Research and development (R&D) expenses for the first quarter of 2024 were $9.7 million, compared to $9.3 million for the same period … research and development tax incentive credits.
General and administrative (G&A) expenses were $3.7 million for each of the three-month periods ended March
8-K
EX-99.1
EQ
Equillium Inc
25 Mar 24
Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights
4:05pm
of 2022.
Research and development (R&D) expenses for the fourth quarter of 2023 were $9.2 million, compared with $8.5 million for the same period … )
(unaudited)
Three Months Ended
December 31,
Year Ended
December 31,
Revenue
Operating expenses:
Research and development
Acquired in-process research
8-K
EX-99.2
ww4iqa0
8 Nov 23
Equillium Announces Data from Phase 1b EQUALISE Study Presented at the 2023 Annual Meeting of the American Society of Nephrology
4:05pm
424B5
lxogzd2d jtx8gvm
5 Oct 23
Prospectus supplement for primary offering
5:23pm
8-K
EX-99.1
jzjmskcw5tfv2y
9 Aug 23
Equillium Reports Second Quarter 2023 Financial Results and Provides Corporate and Clinical Updates
4:06pm
8-K
EX-99.1
of1fqq2cu5up
11 May 23
Equillium Reports First Quarter 2023 Financial Results and Provides Clinical Updates
4:06pm
425
gptuj4tvp2l qbzip
6 Dec 22
Business combination disclosure
4:53pm
425
exvxvf1
6 Dec 22
Business combination disclosure
7:02am
8-K
EX-99.1
grc618h
6 Dec 22
Equillium and Ono Pharmaceutical Announce Exclusive Option and Asset Purchase Agreement for the Development and Commercialization of Itolizumab
7:00am
8-K
9uut12i t8civnp5jl
6 Dec 22
Equillium and Ono Pharmaceutical Announce Exclusive Option and Asset Purchase Agreement for the Development and Commercialization of Itolizumab
7:00am
425
mh1s9dg 6v7x2sz
14 Nov 22
Business combination disclosure
4:20pm
8-K
EX-99.1
g5yjoz3pmwgrq6pe3
14 Nov 22
Equillium Reports Third Quarter 2022 Financial Results and Provides Corporate and Clinical Updates
4:10pm
424B3
mrs78j jur2
10 Nov 22
Prospectus supplement
4:13pm
S-4/A
ek8y9t4
9 Nov 22
Registration of securities issued in business combination transactions (amended)
4:31pm